Severe hypertriglyceridaemia, mixed hyperlipidaemia

Active Ingredient: Fenofibrate

Indication for Fenofibrate

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Fenofibrate is indicated as an adjunct to diet and other non pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
  • Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.

For this indication, competent medicine agencies globally authorize below treatments:

160 mg or 200 mg once daily


Dosage regimens

Regimen A: Oral, 145 milligrams fenofibrate, once daily to meals.

Regimen B: Oral, 160 milligrams fenofibrate, once daily to meals.

Regimen C: Oral, 200 milligrams fenofibrate, once daily to meals.

Detailed description

The recommended dose is 200 mg administered as one capsule or one tablet containing 160 mg fenofibrate taken once daily.

The dose can be titrated up to 267 mg daily administered as one capsule of fenofibrate, if required. This maximum dose is not recommended in addition to a statin.

Patients currently taking one fenofibrate 200 mg capsule can be changed to one fenofibrate 160 mg tablet without further dose adjustment.

Elderly patients (≥65 years old)

No dose adjustment is necessary. The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate <60 mL/min/1.73 m².

Dosage considerations

It should be taken daily during a main meal.

Active ingredient


Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.

Read more about Fenofibrate

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.